IMMUTEP Ltd (IMMP) stock
IMMPNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as PRRUF
$3.48−0.17 (-4.79%)
Close on Nov 13, 2026Market cap $25.64MP/E –Yield –
Immutep r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2026 it was A$76.66M, up 54.0% from the year before. Over ten years it grew 26.9% a year on average. The highest annual figure on record is A$76.66M in fiscal 2026.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | A$76.66M | +54.0% |
| FY2025 | Jun 30, 2025 | A$49.78M | +58.2% |
| FY2024 | Jun 30, 2024 | A$31.47M | +9.3% |
| FY2023 | Jun 30, 2023 | A$28.79M | +13.6% |
| FY2022 | Jun 30, 2022 | A$25.34M | +110.8% |
| FY2021 | Jun 30, 2021 | A$12.02M | -22.8% |
| FY2020 | Jun 30, 2020 | A$15.57M | +13.1% |
| FY2019 | Jun 30, 2019 | A$13.77M | +37.8% |
| FY2018 | Jun 30, 2018 | A$9.99M | +32.7% |
| FY2017 | Jun 30, 2017 | A$7.53M | +6.6% |
| FY2016 | Jun 30, 2016 | A$7.06M | – |
See a number that looks wrong?